The purpose of the study is to look at the effects of two different HIV medications on the body's response to insulin (a hormone that regulates blood sugar levels). This will be done using a method called the 'euglycaemic clamp'

The study will also investigate the effects of these drugs on blood fats and on circulating markers in the blood stream related to blood vessels (vascular inflammation markers).

Raltegravir 400 mg twice daily for the first 14 days of the study. Lopinavir/ritonavir 400/100 mg twice daily for the last 14 days of the study

Drug: Raltegravir then lopinavir/ritonavir

raltegravir 400mg twice daily for first 14 days of study lopinavir/ritonavir 400/100mg twice daily for last 14 days of study

Active Comparator: 2

Lopinavir/ritonavir 400/100 mg twice daily for the first 14 days of the study.

Raltegravir 400 mg twice daily for the last 14 days of the study.

Drug: Lopinavir/ritonavir then raltegravir

lopinavir/ritonavir 400 mg twice daily for the first 14 days of the study raltegravir 400mg twice daily for the last 14 days of the study

Detailed Description:

Subjects will undergo four euglycaemic clamp procedures in order to determine the extent of glucose disposal. The first clamp will be performed prior to the commencement of the first study drug administration, the second one following two weeks of study drug, the third after a two week washout period, prior to commencement of second study drug administration and the fourth after two weeks of the second study drug

Eligibility

Ages Eligible for Study:

18 Years to 60 Years

Genders Eligible for Study:

Male

Accepts Healthy Volunteers:

Yes

Criteria

Inclusion Criteria:

Subjects must have documented negative HIV serology by ELISA and P24 antigen

Subjects must be clinically well males aged between 18 to 60 years

Fasting blood glucose, total cholesterol and triglycerides within normal limits

Other metabolic syndrome or disease process in the opinion of the investigator likely to cause marked disturbance in glucose and lipid homeostasis including hypertension

Receiving on-going therapy with any of the following:

Metabolically active medications

Any lipid-lowering medication

Hormonal agents (oestrogens or androgens)

Glucocorticoids

Beta-blockers

Thiazide diuretics

Thyroid preparations

Psychotropic agents

Anabolic steroids

Megestrol acetate

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00531999